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Abstract: 
Background: Dialysis patients, with frequent co-morbidities, advanced age and frailty, visiting 
treatment facilities frequently are perhaps more prone to SARS-Cov-2 infection and related death - 
the risk-factors and dynamics of which are unknown. The aim of this study was to investigate the 
hospital outcomes in SARS-CoV-2 infected dialysis patients.  
Methods: Data on 224 hemodialysis patients between 02/29/2020 and 05/15/2020 with confirmed 
SARS-CoV-2 were analyzed for outcomes and potential risk factors for death, using competing risk 
regression model assessed by sub-distribution hazards ratio (SHR).  
Results: Crude data analyses suggest an overall case fatality ratio of 22.7(95%CI(17.3-28.3)%) overall 
but that varies across age groups from  11.4(95%CI(0.9-9.2)) in <=50 years old and 32.2(95%CI(17.3-
47.5)%) in >80 years; with 60% of deaths occurring in the first 15 days and 80% within 21 days 
indicating a rapid deterioration towards death after admission. Almost 90% of surviving patients were 
discharged within 28 days. 
Death was more likely than hospital discharge in more frail (WHO performance status 3-4) 
[SHR=2.16(1.25-3.74);p=0.006)], ischemic heart disease [SHR=2.28(1.32-3.94),p=0.003], 
cerebrovascular disease [SHR=2.11(1.20-3.72),p=0.010], smoking history [SHR=2.69(1.33-
5.45),p=0.006], and (completely or partially) hospitalized patients [SHR=10.26.(3.10-33.94),p<.001]; 
and in patients with high CRP [SHR=1.35(1.10-1.67)] and high neutrophil:lymphocyte ratio 
[SHR=1.03(1.01-1.04),p<0.001].  
Our data did not support differences in the risk of death associated with gender, ethnicity, dialysis 
vintage or other comorbidities. However, comparison with the entire dialysis population attending 
these hospitals, and 12.9% being affected, revealed that non-Caucasians (62% vs. 52% in all patients, 
p=0.001) and diabetic patients (54% vs. 22%, p<0.001) were disproportionately affected. 
3 
 
Conclusion: This report discusses the outcomes of a large cohort of dialysis patients with SARS-CoV-2, 
infection affecting more diabetics and non-Caucasians; with a high case fatality ratio, which increased 
significantly with age, frailty, smoking, increasing CRP and neutrophil:lymphocyte ratio at 
presentation.  
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Introduction:  
The SARS-CoV-2 virus is similar to the viruses responsible for SARS and MERS epidemics in 2003 and 
2013. (1) It is highly transmissible between humans and can spread easily in dialysis units, where 
patients are in close contact with each other and their health-care workers at frequent and regular 
intervals. Dialysis patient populations have high representation from elderly co-morbid and often frail 
individuals. (2) In addition they may also be more susceptible to infections, due to abnormal monocyte 
and T lymphocyte responses. (3) The MERS epidemic demonstrated the importance of T cell immunity 
in fighting SARS-CoV-1 infection and the same may be relevant for SARS-CoV-2 infection. (4)  
Measures to protect HD patients have been recommended, including strict protocols for the 
screening, isolation, de-isolation and management of patients within dialysis facilities. (5-7) There are 
few reports of outcomes of COVID-19 in dialysis patients. The case fatality of COVID-19 positive 
hemodialysis (HD) patients in three HD centers in Wuhan varied between 0-16%. (8-10) In one HD 
facility in Northern Italy, the case fatality was as high as 44% (18 out of 41 infected HD patients) from 
a cohort of 98 HD patients. (11) Another hospital in Brescia, Italy admitted 21 COVID 19 positive 
patients; 5(24%) of whom died and 4 were discharged from hospital. (12). The same unit reported 94 
patients of whom 61% required hospital admission and 29% died. (13). In a study from US of 59 
patients 31% died, very similar to a study from Spain where 30% of 36 patients died. (14,15)  
The aim of this observational study was to examine variables which may be associated with risk of 
death in COVID-19 positive HD patients cared for at 3 large NHS hospitals in South London during the 
start of the epidemic until 15th May 2020. We also present the daily incidence of COVID-19 and death 
in this patient cohort as well as the age-dependent case fatality-ratio.    
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Methods  
 
Participant identification  
Dialysis patients were tested for SARS-CoV-2, by nasal and throat swab for real-time RT-PCR (RdRp 
gene) testing if they were symptomatic with persistent cough and or fever, in accordance with 
guidance from Public Health England (PHE). (16) 
Data collection    
Data were collected for SARS-CoV- 2 infected dialysis patients admitted to hospitals or isolation 
hemodialysis facilities across three South London NHS renal centres between 29 February 2020 and 
15 May 2020, including demographics, comorbidities, World Health Organization (WHO) performance 
status, clinical symptoms, laboratory parameters at presentation, hospital management and 
outcomes. Data were sourced from electronic clinical databases including laboratory systems, clinical 
notes and written communications. Aggregate comparative data were obtained from the UK Renal 
Registry. Baseline laboratory results were from the day of presentation or within 24 hours. The 
performance status was based on clinical data on the patients’ usual mobility, exercise tolerance, 
frailty and required assistance.   WHO performance status is a simple tool for assessment of functional 
status and frailty used mostly in the oncology for prognostication and to identify patients suitable for 
treatment (17,18). It estimates the patient’s daily activity and ability to perform activities of daily living 
using a progressive score from 0-5, where 0 indicates a completely active patient, 3 for a patient 
capable of only limited self-care and a value of 5 indicating death. Given the sample size of our data, 
a binary variable based on WHO performance was created upon disease severity, i.e. 0-2 indicating 
less severe and 3-4 indicating a severe frailty. 
 
We have also pulled aggregated statistics regarding the background populations, i.e. that of 
hemodialysis (HD) and peritoneal dialysis (PD) across the three hospitals. The data have been used to 
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assess our sample of COVID-19 positive patients’ characteristics distributions against those in the 
corresponding populations. The study was approved by NHS Research Ethics Committee 20/SW/0077 
and Heath Research Authority IRAS 283130.   
 
Statistical methods  
All the available variables have been graphically explored and summarized according to their nature, 
i.e. means, standard deviations, medians, interquartile limits and ranges for continuous variables and 
proportions for those that were categorical or binary. Log transformation has been performed for 
highly skewed variables where appropriate. Daily time series of admissions and deaths (counts) have 
graphically displayed in Figure 1.   
 
A binary statistical outcome was defined indicating death or discharged alive before 15th May 2020; 
those still under care on that date were set as censored. The analysis modelled the time since 
admission to discharge from care (hospital or isolation dialysis facility) or death during care (hospital 
or outpatient) using the Fine & Grey method for competing risk. Death is the primary statistical event 
of interest and hospital discharge is assumed to be a competing event. A sub-distribution hazard ratio 
(SHR) model has been fit to the data accounting for the censored patients and quantifying the effects 
of each available variable on the risk of death through SHR (19-23). Predicted cumulative incidence 
functions (CIF) are similar to the cumulative distribution functions in classical survival analysis and 
indicate the daily cumulative rate of death or discharge since admission in association with 
each potential explanatory variable. We have also built a multivariable model based on Akaike 
information criterion (AIC- the smaller the value the better the model) used on similar number of 
observations in the data. Sensitivity analyses to missing data have been conducted - results not shown 
or discussed except for smoking variables as all others did not alter the qualitative or quantitative 
conclusions based on complete data. The approach is different from that of cause-specific hazard –
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details on differences has been thoroughly discussed elsewhere (20).A value of SHR greater than 
1 indicates a harmful effect of the corresponding explanatory variable; less than 1 indicates a 
protective effect. Also, a steep increase in the CIFs with time since admission corresponding to death 
indicates a rapid deterioration in patients who died.  A p-value less than 0.05  is interpreted as a 
statistically significant association.  Comparisons with the UK Renal Registry COVID 19 population data 
for dialysis patients have been made using elementary statistical tests according to the nature of 
the variables. Meta-analyses estimating pooled case-fatality ratios in HD population from recent 
published studies around the world are also presented (Table 4). All analyses have been carried out in 
Stata 16 (StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC.).   
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Results   
Demographics and clinical characteristics of SARS-Cov-2 infected hemodialysis 
patients  
Data on 224 hemodialysis patients from three large South London NHS renal centers, admitted to 
hospital or isolation facility between 29 February and 15 May 2020 with confirmed SARS-CoV-2, have 
been collated and analysed to explore potential risk factors for death. Descriptive statistics for this 
population, survival status until 15 May and associations with SHR of death vs. Survival are presented 
in Table 1. Within this cohort of patients 51 (22.8%) died, 154 (68.8%) were discharged alive and 19 
(8.5%) were still under care in hospital or an isolation facility when we stopped the data collection 
(censored). The first hospital admission was on 29 February and the daily time series of admissions 
showed a steady increase until the peak between 30 March and 2 April, followed by a decline in 
admissions (Figure 1). The first death occurred on 22 March 2020.  
The mean patient age was 66±14(SD) years with 133 (59%) men, 85 (38%) Caucasian, 182 
(81%) hypertensives, 120 (54%) diabetics, 64 (29%) ischemic heart disease, 49 (22%) cerebrovascular 
disease, 40 (18%) heart failure with reduced ejection fraction (HFrEF), 56 (25%) chronic lung 
disease and 33 (15%) with history of cancer (Table 1). Comparative results with the overall HD 
population are presented in Table 2. 
Smoking status was reported in 165 (73.7%) patients and 71 (32%) were ex or current 
smokers. Median (Q1-Q3) dialysis vintage was 2.82 years (1.11-5.46 years). Overall, 124 (55.4%) 
patients dialyzed with a fistula or arteriovenous graft and 98 (43.8%) patients with a line. WHO 
performance status at the time of presentation was 0, 1 or 2 in 134 (60%) and 3 or 4 in 83 
(37%) patients.   Median (Q1-Q3) serum albumin at the last routine monthly blood review prior to 
presentation was 34 g/L (30-38) and 56 (34%) patients were taking an ACE inhibitor/Angiotensin 
receptor blocker (ACEi/ARB) at the time of COVID-19 diagnosis.   
9 
 
Symptoms at presentation were fever in 186 (83%), shortness of breath in 92 (41%), dry 
cough in 82 (37%), productive cough in 37 (17%), diarrhea in 30 (13%), vomiting in 30 
(13%), headache in 20 (9%), aches and pains in 37 (17%) patients and only 10 (4.5%) patients were 
asymptomatic.    
At presentation the median (Q1-Q3) blood C-reactive protein (CRP) was 74 mg/L (32-129), white 
cell count 5.4 x 109/L (3.9-7.4), neutrophil count 3.8 x 109/L (2.6-5.9), lymphocyte count 0.80 x 109/L 
(0.58-1.1), neutrophil to lymphocyte ratio median (Q1-Q3) 4.7 (3.1-7.8), hemoglobin 105 g/L( 97-114).  
Management of SARS-CoV-2 infected hemodialysis patients  
Overall, 81 (36%) of hemodialysis patients were managed exclusively as outpatients dialysing initially 
in isolation facilities belonging to the hospitals and then discharged to satellite units when clinically 
improved; 115 (51.8%) were cared for exclusively as inpatients and 28(12%) were managed as 
outpatients before hospitalization. .  
Of these 143 (64%) patients who were admitted to hospital, a ‘ceiling of care’ was determined, 
meaning the highest level of medical intervention deemed appropriate should the patient’s clinical 
condition deteriorate. This decision was made by the medical team taking into account the patient’s 
wishes and whether the patient was likely to benefit from more invasive care. A ward-based ceiling of 
care decision was made for 73 (51%) patients, escalation for non-invasive ventilation in 24 (17%) and 
for mechanical ventilation in 46 (32%).  
Ninety-two (64%) of the hospitalized patients required maximum respiratory support from respiratory 
support devices that could be delivered on the ‘ceiling of care’ ward setting, including nasal cannulae 
and non-rebreathing masks. There were 12 hospitalized patients that required non-invasive 
ventilation (NIV). Only 11 (8%) patients of hospitalized patients were ultimately admitted to the 
intensive care unit (ICU), with 9 patients requiring mechanical ventilation.    
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At the end of follow-up, 19 (8.5%) of patients were still inpatients because of their COVID-19 related 
illnesses.  
Associations with the SHR of death vs. discharge in SARS-CoV-2 infected 
hemodialysis patients   
At the end of follow-up, 51 (22.8%) hemodialysis patients had unfortunately died (time series in Figure 
1), 154 (68.8%) were discharged from either inpatient care or outpatient isolation hemodialysis and 
19 (8.5%) were still under clinical care.  
Figure 2 showing the cumulative incidence of death suggests that patients deteriorated relatively 
quickly, at a steadily increasing pace during the first 23 days of admission. The daily incidence of 
discharge after admission increased sharply between 5-20 days since admission. This latter trend 
slowed down afterwards - driven by 38 patients who required long (21-55 days) hospitalization. The 
effects of age and other variables on the dynamics of death and hospital discharge can be seen in 
Table 1.  
Patients that required admission to hospital were 6.83 (95%CI 2.07-22.48) times more likely to die 
than patients managed exclusively or partially as outpatients.  Based on these data, there is not 
enough evidence to suggest that gender, ethnicity, BMI or dialysis vintage were associated with death 
in these patients (all corresponding p-values for SHR >0.05).  
A 5-year increase in the age at admission is associated with an increase in the SHR of death vs. 
discharge of 1.16 (1.03-1.30), p=0.013. There was an average 22.8% case-fatality ratio, which exhibited 
heterogeneity across the age groups in this cohort, with 11.4% of deaths among patients under 50 
years of age, 33.3% in those 75-80 years of age and 32.4% in those over 80 years of age. 
Smoking history was associated with a increased sub-hazard of death by almost 3 times (2.69 (1.33-
5.45)) compared to no smoking history. Given the great deal of missing information for this variable 
(26%) a sensitivity analysis in which all these patients were assumed to be non-smokers still preserves 
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the harmful effect of smoking, i.e. SHR=1.78 (1.03-3.08), p=0.041. There is also some evidence 
(p=0.003) and (p=0.01) for a higher chance of death in ischemic heart disease and cerebrovascular 
disease patients compared with those without these comorbidities, respectively. In addition, those 
with a WHO frailty score of 3-4 were 2.16 (95%CI (1.25-3.74)) times more likely to die compared with 
those with a WHO score of 0-2. The data presented in this population were consistent with no effect 
of ACEi/ARB on the hazard of death (p=0.518).  
The only evidence for an association of death with symptoms on admission was with shortness of 
breath (SHR=2.32 (1.29-4.17. p=0.005)) (Table 1). Among patients who died compared to patients who 
were discharged alive, blood CRP concentration was higher (median (Q1-Q3) 113 (47-212) vs. 65 (28-
104), log lymphocyte count was lower and neutrophil:lymphocyte ratio was higher (median (Q1-Q3) 
7.2 (4.2-13.4) vs.  4.3 (2.9-6.7) (Figure 3). Furthermore, each unit increase in neutrophil:lymphocyte 
ratio was associated with a 3% (1.7%-5%) increase in SHR for death vs. hospital discharge and similarly 
each 10 mg/L rise in CRP was associated with a 3% (1%-5%) increased SHR of death. Our multivariable 
model included the predictors which remain strong (p<0.05) and for which the AIC value was the 
smallest. The WHO score includes elements of age so the two confound each other as expected. 
However, the model including the age, neutrophil:lymphocyte ratio and hospital management was 
better than including WHO score neutrophil:lymphocyte ratio and hospital management (AIC= 
471.933 vs. AIC= 473.400, respectively). The adjusted effects of these variables are only slightly 
modified compared to their univariate counterparts (Table1). 
Demographics and clinical characteristics and outcomes of SARS-CoV-2 infected 
peritoneal dialysis patients   
Among the 10 SARS-CoV-2 infected PD patients aged 69.5 (59-75) year [median (Q1-Q3)], with 8 males; 
5 Caucasians; 3 smokers and 6 diabetics; 1 was managed as an outpatient. Of the 9 inpatients, 3 
required NIV, 2 required ICU admission and 1 required mechanical ventilation. Six of the admitted 
patients (60% of the total) died and 4 were discharged alive.  
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Comparison of SARS-CoV-2 patients with reference populations  
Unless otherwise specified, the reference populations are collectively those patients who have their 
usual dialysis provided by the South London renal centers (Table 2).  
Up until 15 May 2020, 224 (approximately 13%) of all HD patients (1727) and 10 (approximately 4.4%) 
of all PD patients (228) from the 3 renal centers tested positive for COVID-19. Of those that were 
COVID-19 positive, 51 (22.8%) HD patients and 5 (50%) PD patients have died, such that approximately 
2.96% of all HD patients and approximately 2.6% of all PD patients managed at the three centers died 
from COVID-19 disease during the period of data collection.  
The demographic data for COVID-19 positive patients presented here was broadly consistent with that 
of the HD (p=0.383) and PD (p=0.137) populations respectively across the 3 hospitals. The distribution 
of gender in our COVID-19 positive cohort was also similar to that observed in the local dialysis 
populations (p=0.066 for HD and p=0.198, respectively). There was, however, a suggestion that SARS-
CoV-2 infections seemed to have affected more non-Caucasian HD patients than Caucasian patients 
(Table 2, p=0.001) despite no differences between case-fatality ratios supported by these data. The 
numbers in the PD population are too small for meaningful analyses using individual records.  The 
proportion of diabetics among COVID-19 positive patients is also higher than might be expected from 
the reference dialysis populations (54% vs. 46% in HD, p<0.001 and 60% vs. 19% in PD, p=0.004). Our 
data suggest some evidence that the case-fatality ratio is higher (p=0.015) in PD (6/10) patients than 
in HD (51/224).  
Also, based on the size of the dialysis population of the renal centers, approximately 13% (224/1737) 
were affected with the SARS-CoV-2 infection and 2.96% (51/1737) died by the date when we stopped 
data collection. 
The case fatality ratio described for our dialysis patients that tested COVID-19 positive appears to be 
commensurate with national renal data shown in Table 3 by the time of our censoring. (24)  
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The numbers in the PD COVID-19 positive patients are too small for meaningful analyses using 
individual records as in hemodialysis COVID 19 positive patients. 
In a meta-analysis based on another six similar studies the case fatality ratio was 24% (17-31%) and 
including the present study was 23% (18-29%). There was some high level of heterogeneity in the data 
mainly caused by China -Wuhan estimate but we felt that the study should be left in the analysis 
(Figure 4).  
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Discussion  
In this study of SARS-CoV-2 infected dialysis patients the case fatality ratio was high, 22.8%. The 
patients who died, compared to those recovered, were older, more likely to be smokers and 
hospitalized, more likely to have ischemic and cerebrovascular disease and have worse WHO 
performance status. COVID-19 disease was observed more frequently in diabetic and non-white 
patients.  
 The infection rate of 13% in our hemodialysis population likely represents an underestimate, as only 
patients with symptoms were screened, therefore missing asymptomatic and falsely negative PCR 
COVID-19 patients. This has been illustrated in a recent study of 356 HD patients, where 22% were 
PCR positive for COVID-19 with symptom-based screening, however the seroprevalence rate was 36%, 
therefore with 40% of patients with positive antibodies having been either asymptomatic or negative 
on PCR testing (25).  
The impact of age is clearly visible from Figure 1 which shows that more than 30% of patients above 
the age of 75 years died as opposed to less than 15% of the patients who were under 60 years of age.  
The case fatality ratio presented in this report, is broadly consistent with that observed in other 
reports of dialysis patients with COVID 19 as seen in the meta-analysis of six studies from Europe, Asia 
and North-America (Table 4); and similar to other hospitalised patients with COVID-19 in the UK and 
elsewhere, but lower than patients admitted to ICU. (26). 
In our dialysis population, smokers were more likely to die, which may be due to the fact that the 
SARS-COV-2 virus is an airborne disease which predominantly affects the lungs. Smokers and 
individuals with COPD have recently been reported to have increased expression of ACE-2 receptors, 
which is the site for SARS-Co-V-2 entry into cells, in small airway epithelial cells. This may explain why 
current and ex-smokers have poorer COVID-19 related respiratory outcomes. (27). The evidence for 
this finding is preserved even after sensitivity analysis (Table 1).   
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The presence of healthy adaptive immunity, which requires the presence of healthy T&B lymphocyte 
populations, is important in mounting an appropriate response to viral infection, which may be 
defective in dialysis patients. (28)  In our study, patients who died had a higher neutrophil count, lower 
lymphocyte (log) count and a higher neutrophil:lymphocyte ratio at presentation. This is consistent 
with earlier reports in the general population where poor prognosis was associated with low 
lymphocyte and higher neutrophil:lymphocyte ratio in the blood. (29,30) . The effects of age, 
neutrophil:lymphocyte ratio in the blood and hospital management remain strong even after adjusting 
one for another (Table 1).  
Compared to the aggregate data from the haemodialysis population in the three hospitals, the 
patients who were infected with SARS-CoV-2 had a higher proportion of diabetics than non-diabetics 
and a higher proportion of non-Caucasians compared to Caucasians. This is also broadly consistent 
with what is seen in the general population, particularly in the UK. (31,32) 
The investigation into the impact of frailty score of COVID-19 in hemodialysis patient is a major 
strength of the study.  In this patient cohort, 51% of inpatients had an established ceiling of care 
decision for ward-based care and within this group approximately 1 in 2 patient’s died, totalling 74% 
of the total case fatality. As shown in Table 4, the ward-based care decision seemed appropriate as 
the patients within this category were older, more frail and co-morbid than those for treatment 
escalation and for those that ultimately were admitted to ICU.  Only one out of the nine mechanically 
ventilated patients was discharged alive, whereas six patients died and the other two remained 
ventilator dependent, indicating poor outcome. 
 
This study has several limitations. First, data were collected retrospectively through electronic health 
records and medical notes used for routine clinical care and some data for those managed as 
outpatients were missing.    We did not systematically collect detailed data on dialysis and non-dialysis 
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treatments given to patient. In the UK, the Chief Medical Officers strongly discouraged the use of off-
licence treatments outside of a clinical trial. Treatment was therefore largely supportive unless 
patients participated in a clinical trial. There were 20 HD and 3 PD patients in this cohort who did 
participate in the RECOVERY trial (randomly assigned to supportive care (12) or to one of four 
treatments: lopinavir-ritonavir (2), low dose dexamethasone (3), hydroxychloroquine (3), or 
azithromycin (3)), and it is possible that these interventions may have affected their clinical course 
and outcomes.  
 
Conclusions 
 
This report describes the outcomes of dialysis patients with COVID-19, more likely to be diabetic and 
non-Caucasian; from a large cohort of dialysis patients from 3 NHS hospitals in south London. Case 
fatality ratio among those infected with SARS-CoV-2 was high, 22.8%, in line with the pooled estimate 
from the meta-analysis. The patients who died, compared to those who survived, were older, more 
likely to be smokers, cardiovascular disease and have worse WHO performance status. The case 
fatality ratio in this patient population, known to have high burden of co-morbidities, is broadly 
comparable to other reports in SARS-Cov-2 dialysis patients, the UK dialysis population and rates of 
hospital deaths in the UK population.  
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Tables 
Table 1 
 VARIABLES NAME SUMMARY 
TYPE/CATEGORY 
ALL 
PATIENTS 
 
DISCHARGE 
ALIVE 
 
DIED 
 
 
STILL IN CARE 
 
 
SUB-DISTRIBUTION HAZARD 
RATIO 
ADJUSTED SUB-
DISTRIBUTION HAZARD 
RATIO (210 obs. - 94%) 
   224 154 (68.75%) 51 (22.77%) 19 (8.48%) DIED vs. SURV p-value NO DIED vs. SURV p-value 
D
e
m
o
gr
ap
h
ic
s 
              
GENDER Male 133 (59.38%) 89 (57.79%) 35 (68.63%) 9 (47.36%) 1     
 Female 91 (40.63%) 65 (42.21%) 16 (31.37%) 10 (52.63%) 0.66 (0.36-1.20) 0.172 220   
ETHNICITY White 85 (37.95%) 54 (35.06%) 21 (41.18%) 10 (52.63%)      
(binary) Other 139 (62.05%) 100 (64.94%) 30 (58.82%) 9 (47.36%) 0.85 (0.49-1.48) 0.571 220   
ETHNICITY White 85 (37.95 %) 54 (35.07%) 21 (41.18%) 10 (52.63%)      
(detailed) South Asian 41 (18.30%) 27 (17.53%) 11 (21.57%) 3 (15.79%)      
 East Asian 8 (3.57%) 5 (3.25%) 3 (5.88%) 0 (0%)      
 Black 77 (34.38 %) 59 (38.31%) 13 (25.49%) 5 (26.32%)      
 Other 13 (5.80%) 9 (5.84%) 3 (5.88%) 1 (5.26%)      
SMOKING Never 94 (41.96%) 71 (46.10%) 12 (23.53%) 11 (57.89%) 1     
status Ever 71 (31.70%) 43 (27.92%) 22 (43.14%) 6 (31.58%) 2.69 (1.33-5.45)  0.006 161   
 Missing 59 (26.34%) 40 (25.97%) 17 (33.33%) 2 (10.53%)      
Missing=NO Never 153 (68.30%) 111 (72.08%) 29 (56.86%) 13 (68.42%) 1     
 Ever 71 (31.70%) 43 (27.92%) 22 (43.14%) 6 (31.58%) 1.78 (1.03-3.08) 0.041 220   
Missing=YES Never 94 (41.96%) 71 (46.10%) 12 (23.53%) 11 (57.89%) 1     
 Ever 130 (58.04%) 83 (53.90%) 39 (76.47%) 8 (42.11%) 2.57 (1.34-4.93) 0.005 220   
AGE Mean (SD) 65.83 (14.39) 63.90 (14.43) 70.47 (13.79) 69 (12.77) 1.16 (1.03-1.30) 0.013 220 1.15 (1.002-1.31) 0.047 
at admission Median (Q1-Q3) 67.5 (57-77) 65 (57-76) 73 (62-80) 73 (59-81)      
(5 yrs effect) Range 25-90 26-90 25-90 38-82      
BMI Mean (SD) 28.2 (7.6) 28.5 (8) 26.9 (6.3) 28.9 (7.9) 0.97 (0.93-1.01) 0.186 193   
(kg/m2) Median (Q1-Q3) 26.3 (23.1-31.2) 26.2 (23.2-31.4) 26.1 (21.7-30.0) 26.6 (16.5-42)      
 Range 16.5-57.8 18.7-57.8 17.4-49.2 16.5-42.1      
 Missing 27 (12.05%) 17 (11.04%) 8 (15.67%) 2 (10.53%)      
 WHO 0 16 (7.14%) 15 (9.74%) 1 (1.96%) 0 (0%)      
   
C
o
m
o
rb
id
it
ie
s 
performance 1 51 (22.77%) 42 (27.27%) 6 (11.76%) 3 (15.79%)      
status  2 67 (29.91%) 43 (27.92%) 16 (31.37%) 8 (42.11%)      
detailed  3 54 (24.11%) 34 (22.08%) 15 (29.41%) 5 (26.32%)      
 4 29 (12.95%) 13 (8.44%) 13 (25.49%) 3 (15.79%)       
 Missing 7 (3.13%) 7 (4.55%) 0 (0%) 0 (0%)      
WHO 0-2 134 (59.82%) 100 (64.94%) 23 (45.10%) 11 (57.90%)      
performance 3-4 83 (37.05% 47 (30.52%) 28 (54.90%) 8 (42.11%) 2.16 (1.25-3.74)  0.006 213   
binary Missing 7 (3.13%) 7 (4.55%) 0 (0%) 0 (0%)      
History of cancer  No 189 (84.38%) 132 (85.71%) 42 (82.35%) 15 (78.95%)      
 Yes 33(14.73%) 20 (12.99%) 9 (17.65%) 4 (21.05%) 1.25 (0.613-2.57) 0.537 218   
 Missing 2(0.89%) 2 (1.30%) 0 (0%) 0 (0%)      
Hypertension No 41(18.30%) 24 (15.58%) 8 (15.69%) 9 (47.37%)      
 Yes 182(81.25(%) 129 (83.80%) 43 (84.31%) 10 (52.63%) 1.27 (0.61-2.66) 0.528 219   
 Missing 1(0.45%) 1 (0.65%) 0 (0%) 0 (0%)      
DIABETES No 103(45.98%) 71 (46.10%) 21 (41.18%) 11 (57.90%)      
 Yes 120 (53.57%) 82 (53.25%) 30 (58.82%) 8 (42.11%) 1.31 (0.76-2.28)  0.335 219   
 Missing 1(0.45%) 1 (0.65%) 0 (0%) 0 (0%)      
HFrEF No 181 (80.80%) 124 (80.52%) 40 (78.43%) 17 (89.47%)      
 Yes 40(17.86%) 27 (17.53%) 11 (21.57%) 2 (10.53%) 1.38 (0.69-2.73)  0.363 217   
 Missing 3 (1.34%) 3 (1.95%) 0 (0%) 0 (0%)      
CHRONIC LUNG NO 168 (75%) 115 (74.68%) 39 (76.47%) 14 (73.68%) NA     
DISEASE Asthma 16 (7.14%) 13 (8.44%) 0 (0%) 3 (15.79%)      
DETAILED Bronchiectasis 1 (0.45%) 1 (0.65%) 0 (0%) 0 (0%)      
 COPD 15 (6.70%) 6 (3.90%) 8 (15.69%) 1 (5.26%)      
 Fibrosis 4 (1.79%) 3 (1.95%) 1 (1.96%) 0 (0%)      
 Other 17 (7.59%) 13 (8.44%) 3 (5.88%) 1 (5.26%)      
CHRONIC LUNG No 168 (75%) 115 (74.68%) 39 (76.47%) 14 (73.68%)      
22 
 
DISEASE Yes 56 (25%) 39 (25.33%) 12 (23.53%) 5 (26.32%) 0.9 2 (0.48-1.77)   0.810    220   
Ischaemic heart 
disease 
No 157 (70.09%) 116 (75.33%) 28 (54.90%) 13 (68.42%)      
Yes 64 (28.57%) 35 (22.72%) 23 (45.10%) 6 (31.58%) 2.28 (1.32-3.94)  0.003 217   
 Missing 3 (1.34%) 3 (1.95%) 0 (0%) 0 (0%)      
CEREBROVASCULAR 
DISEASE 
No 173 (77.23%) 124 (80.52%) 33 (64.71%) 16 (84.21%)      
Yes 49 (21.88%) 28 (18.18%) 18 (35.29%) 3 (15.79%) 2.11 (1.20-3.72)  0.010 218   
 Missing 2 (0.89%) 2 (1.30%) 0 (0%) 0 (0%)      
 Length of stay Mean (SD) 19.01 (12.4) 17.4 (9.8) 15.6 (10.3) NA      
H
o
sp
it
al
 m
an
ag
e
m
e
n
t 
 Median (Q1-Q3) 16 (11-23.5) 16 (11-22) 14 (7-19)       
 Range 1-60 1-55 2-43       
 Missing 4 (1.8%) 4 (2.60%) 0 (0%)       
MANAGE OUTPATIENT 81 (36.16%) 78 (50.65%) 3 (5.88%) 0 (0%) 1  220   
 OUT to IN 28 (12.50%) 18 (11.69%) 6 (11.77%) 4 (21.05%) 6.40 (1.55-26.36) 0.010  5.50 (1.33-22.79) 0.040 
 INPATIENT 115 (51.34%) 58 (37.66%) 42 (82.35%) 15 (78.95%) 11.24 (3.38-37.37) <0.001  8.56 (2.54-28.83) 0.001 
MANAGE-binary OUTPATIENT 81 (36.16%) 78 (50.65%) 3 (5.88%) 0 (0%) 1 <0.001 220   
 PART or TOTAL  143 (63.84%) 76 (49.35%) 48 (94.12%) 19 (100%) 10.26 (3.10-33.94)     
On ACEi/ARB No 150 (66.96%) 98 (63.64%) 37 (72.55%) 15 (78.95%)      
 Yes 70 (31.25%) 53 (34.42%) 14 (27.45%) 3 (15.79%) 0.82 (0.44-1.52) 0.518 216   
 Missing 4 (1.79%) 3 (1.95%) 0 (0%) 1 (5.26%)      
CEIL OF CARE** Ward 73 (51.05%) 31 (38.27%) 34 (73.91%) 8 (50.00%) 1     
only 143 obs NIV 24 (16.78%) 17 (20.99%) 5 (10.87%) 2 (12.50%) 0.36 (0.14-0.94) 0.036 141   
 Mechanical 
ventilation 
46 (32.17%) 33 (40.74%) 7 (15.22%) 6 (37.50%) 0.25 (0.12-0.56) 0.001    
           
MAXIMUM NONE 67 (29.91%) 64 (41.56%) 0 (0%) 3 (15.79%) NA     
BREATHING  Nasal cannula 60 (26.79%) 40 (25.97%) 14 (27.45%) 6 (31.58%)      
SUPPORT Vent/Face mask 32 (14.29%) 6 (3.90%) 23 (45.10%) 3 (15.79%)      
 NIV 12 (5.36%) 7 (4.55%) 4 (7.84%) 1 (5.26%)      
 Mechanical 
Ventilationd 
9 (4.02%) 1 (0.65%) 6 (11.77%) 2 (10.53%)      
 Missing 44 (19.64%) 36 (23.38%) 4 (7.84%) 4 (21.05%)      
Dialysis  Fistula or AVG 124 (55.36%) 89 (57.79%) 24 (47.06%) 11 (57.90%) 1     
access Line 98 (43.75%) 64 (41.56%) 26 (50.98%) 8 (42.11%) 1.34 (0.77-2.32) 0.298 218   
 Missing 2 (0.89%) 1 (0.65%) 1 (1.96%) 0 (0%)      
Dialysis vintage Mean (SD) 4.092 (4.46) 3.99 (4.43) 4.44 (4.76) 3.94 (4.46) 1.13 (0.86-1.48) 0.393 209   
5-yrs effect Median (Q1-Q3) 2.82 (1.11-5.46) 2.57 (1.05-5.27) 3.11 (1.17-5.55) 3.94 (1.2-5.23)      
 Range 0.003-24.7 0.003-24.7 0.022-22.9 0.22-16.3      
 Missing 11 (4.91%) 8 (5.20%) 2 (3.92%) 1 (5.26%)      
IMMUNO No 197 (87.95%) 135 (87.66%) 47 (92.16%) 15 (78.95%)      
SUPRESSION Yes 23 (10.27%) 16 (10.39%) 4 (7.84%) 3 (15.79%) 0.73 (0.27-1.94) 0.523 216   
 Missing 4 (1.79%) 3 (1.95%) 0 (0%) 1 (5.26%)      
ITU ADMISSION No 207 (92.41%) 148 (96.10%) 44 (86.28%) 15 (78.95%)      
 Yes 11 (4.91%) 3 (1.95%) 6 (11.77%) 2 (10.53%)      
 Missing 6 (2.68%) 3 (1.95%) 1 (1.96%) 2 (10.53%)      
NO PREV TX 0 206 (91.96%) 142 (92.21%) 47 (92.16%) 17 (89.47%) 1     
 1-2 14 (6.24%) 9 (5.84%) 4 (7.84%) 1 (5.26%) 1.40 (0.54-3.67) 0.488 216   
 Missing 4 (1.78%) 3 (1.95%) 0 (0%) 1 (5.26%)      
Transplant WAIT LIST No 201 (89.73%) 135 (87.66%) 48 (94.12%) 18 (94.74%) 1     
 Yes 16 (7.14%) 14 (9.09%) 2 (3.92%) 0 (0%) 0.52 (0.123-2.040) 0.356 215   
  Missing 7 (3.13%) 5 (3.25%) 1 (1.96%) 1 (5.26%)      
 FEVER No 58 (25.89%) 40 (25.97%) 17 (33.33%) 1 (5.26%)      
Sy
m
p
to
m
s 
 Yes 138 (61.61%) 96 (62.34%) 31 (60.78%) 11 (57.90%) 0.72 (0.40-1.29) 0.269 193   
 Missing 28 (12.50%) 18 (11.69%) 3 (5.88%) 7 (36.84%)      
SOB No 105 (46.88%) 85 (55.20%) 17 (33.33%) 3 (15.79%)      
 Yes 92 (41.07%) 52 (33.77%) 31 (60.78%) 9 (47.37%) 2.32 (1.29-4.17) 0.005 194   
 Missing 27 (12.05%) 17 (11.04%) 3 (5.88%) 7 (36.84%)      
DRY COUGH No 116 (51.79%) 84 (54.55%) 25 (49.02%) 7 (36.84%)      
 Yes 82 (36.61%) 54 (35.07%) 23 (45.10%) 5 (26.32%) 1.31 (0.74-2.29) 0.352 195   
23 
 
 Missing 26 (11.61%) 16 (10.39%) 3 (5.88%) 7 (36.84%)      
PRODUCTIVE  No 160 (71.43%) 111 (72.08%) 39 (76.47%) 10 (52.63%)      
COUGH Yes 37 (16.52%) 25 (16.23%) 10 (19.61%) 2 (10.53%) 1.14 (0.57-2.26) 0.710 194   
 Missing 27 (12.05%) 18 (11.69%) 2 (3.92%) 7 (36.84%)      
HEADACHE No 176 (78.57%) 122 (79.22%) 44 (86.27%) 10 (52.63%)      
 Yes 20 (8.93%) 14 (9.09%) 4 (7.84%) 2 (10.53%) 0.76 (0.27-2.10) 0.593 193   
 Missing 28 (12.50%) 18 (11.69%) 3 (5.88%) 7 (36.84%)      
VOMITING No 166 (74.11%) 118 (76.62%) 39 (76.47%) 9 (47.37%)      
 Yes 30 (13.39%) 18 (11.69%) 9 (17.65%) 3 (15.79%) 1.29 (0.63-2.65) 0.483 193   
 Missing 28 (12.50%) 18 (11.69%) 3 (5.88%) 7 (36.84%)      
ACHES  No 157 (70.10%) 110 (71.43%) 38 (74.51%) 9 (47.37%)      
& PAINS Yes 39 (17.42%) 26 (16.88%) 10 (19.61%) 3 (15.79%) 1.06 (0.53-2.15) 0.861 193   
 Missing 28 (12.50%) 18 (11.69%) 3 (5.88%) 7 (36.84%)      
DIARHOEA No 165 (73.66%) 113 (73.38%) 43 (84.31%) 9 (47.37%)      
 Yes 30 (13.39%) 23 (14.94%) 5 (9.80%) 2 (10.53%) 0.60 (0.24-1.51) 0.275 192   
 Missing 29 (12.95%) 18 (11.69%) 3 (5.88%) 8 (42.11%)      
SYMPTOMS No 186 (83.04%) 127 (82.47%) 47 (92.16%) 12 (63.16%)      
 Yes 10 (4.46%) 9 (5.84%) 1 (1.96%) 0 (0%) 0.37 (0.05-2.95) 0.350 193   
 Missing 28 (12.50%) 18 (11.69%) 3 (5.88%) 7 (36.84%)      
 Haemoglobin (g/L) Mean (SD) 105.04 (15.28) 104.13 (13.74) 108.49 (18.383) 103.06 (17.38) 1.10 (0.99-1.22) 0.092 210   
B
lo
o
d
 a
n
al
ys
e
s 
 Median (Q1-Q3) 105 (97-114) 105 (96-113) 107 (99-120) 102.5 (91-116)      
 Range 70-145 73-145 70-141 72-136      
 Missing 11 (4.91%) 5 (3.25%) 2 (3.92%) 18 (94.74%)      
CRP (mg/L)    Mean (SD) 103.62 (101.8) 89.26 (92.13) 140.76 (116.6) 115.14 (110.2) 1.03 (1.01-1.05) 0.005 198   
(10-unit SHR effect) Median (Q1-Q3) 74 (31.8-129.3) 65 (28-103.8) 113 (47-212) 76.4 (38.7-
183) 
     
 Range 1.1-596.5 1.1-596.5 4.4-471 6-368      
 Missing 23 (10.27%) 18 (11.69%) 4 (7.84%) 1 (5.26%)      
CRP  Mean (SD) 4.074 (1.20) 3.91 (1.29) 4.51 (1.10) 4.203 (1.22) 1.44 (1.07-1.93) 0.015 198   
(log scale) Median (Q1-Q3) 4.30 (3.46-4.86) 4.17 (3.33-4.64) 4.73 (3.85-5.36) 4.32 (3.7-5.21)      
 Range 0.095-6.39 0.095-6.39 1.48-6.15 1.97-5.91      
 Missing 23 (10.27%) 18(11.69%) 4 (7.84%) 1 (5.26%)      
WHITE CELL COUNT Mean (SD) 6.16 (3.175) 5.65 (3.029) 7.39 (3.158) 6.92 (3.476) 1.70 (1.22-2.37) 0.002 210   
original scale Median (Q1-Q3) 5.38 (3.9-7.43) 5.1 (3.5-6.6) 6.9 (5.22-9.7) 6.16 (4.27-8.1)      
(5-unit effect) Range 1.65-18.9 1.65-18.9 1.8-15.3 2.3-15.2      
WHITE CELL COUNT Mean (SD) 1.70 (0.49) 1.62 (.50) 1.90 (0.47) 1.82 (0.50) 2.53 (1.45-4.42) 0.001 210   
(log scale) Median (Q1-Q3) 1.68 (1.36-2.01) 1.63 (1.25-1.89) 1.93 (1.65-2.27) 1.81 (1.45-2.1)      
 Range 0.5-2.94 0.50-2.94 .59-2.73 0.83-2.72      
 Missing 11 (4.91%) 8 (5.20%) 2(3.92%) 1 (5.26%)      
NEUTROPHIL COUNT Mean (SD) 4.67 (2.99) 4.22 (2.88) 5.91 (3.02) 4.98 (2.97) 1.80 (1.26-2.56) 0.001 210   
(x109/L) Median (Q1-Q3) 3.8(2.6-5.93) 3.5 (2.3-5.2) 5.4 (3.57-7.9) 4.52 (3-6.1)      
original scale Range 0.68-17.5 0.68-17.5 1.1-13.9 1.2-12.6      
NEUTROPHIL COUNT Mean (SD) 1.36 (0.61) 1.26 (0.59) 1.64 (0.56) 1.43 (0.64) 2.30 (1.45-3.66) <0.001 210   
(log scale) Median (Q1-Q3) 1.34 (0.96-1.78) 1.25 (0.83-1.65) 1.67 (1.27-2.07) 1.51 (1.1-1.81)      
 Range -0.39-2.86 -0.39-2.86 0.10-2.63 0.18-2.53      
 Missing 11 (4.91%) 8 (5.20%) 2 (3.92%) 1 (5.26%)      
LYMPHOCYTE COUNT Mean (SD) 0.903(0.49) 0.889 (0.403) 0.815 (0.56) 1.27 (0.73) 0.59 (0.23-1.53) 0.276 210   
(x109/L) Median (Q1-Q3) 0.8 (.58-1.1) 0.8 (0.6-1.1) 0.7 (0.4-1) 1.2 (0.8-1.6)      
original scale Range 0.1-3.6 0.2-2.3 0.1-3.4 0.4-3.6      
LYMPHOCYTE COUNT Mean (SD) -0.23 (0.52) -0.22(0.45) -0.39 (0.63) 0.10 (0.54) 0.52 (0.31-0.86) 0.012 210   
(log scale) Median (Q1-Q3) -0.22 (-0.54-
0.10) 
-0.22 (-1.08-
0.70) 
-0.36 (-0.92-
0.00) 
0.18 (-0.22-
0.47) 
     
 Range -1.3-1.28 -1.61-0.83 -2.30-1.22 -0.92-1.28      
 Missing 11 (4.91%) 8 (5.20%) 2 (3.92%) 1 (5.26%)      
NEUT/LYMP ratio Mean (SD) 6.9 (8.4) 5.7 (4.97) 11.6 (14.3) 4.8 (3.2) 1.03 (1.017-1.05) <0.001 210 1.03 (1.01-1.04) <0.001 
 Median (Q1-Q3) 4.7 (3.1-7.8) 4.30 (2.9-6.7) 7.2 (4.2-13.4) 4.1 (2.1-7.4)      
 Range 0.7-93 0.9-32 0.7-93 0.9-11.98      
NEUT/LYMP ratio Mean (SD) 1.59 (.80) 1.47 (.71) 2.03 (.90) 1.33 (0.73) 2.10 (1.54-2.87) <0.001 210   
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(log scale) Median (Q1-Q3) 1.54 (1.12-2.05) 1.46 (1.05-1.91) 1.98 (1.43-2.60) 1.40 (0.76-
1.99) 
     
 Range -0.31-4.53 -0.13-3.47 -0.31-4.53 -0.07-2.48      
 Missing 11 (4.91%) 8 (5.20%) 2 (3.92%) 1 (5.26%)      
ALBUMIN (g/L) Mean (SD) 33.66 (6.32) 34.25 (6.01) 31.88 (7.14) 33 (6.26) 0.80 (0.64-1.01) 0.059 200   
(5-unit effect)  Median (Q1-Q3) 34 (30-38) 35 (31-39) 33 (29-37) 33.5 (29-35)      
  Range 13-47 16-47 13-45 22-43      
  Missing 20 (8.93%)  7 (4.55%) 8 (15.69%) 5 (26.32%)      
Table 1: Demographic, clinical characteristics and hospital management features of all 224 SARS-
CoV-2 positive patients from St George’s, King’s and St Helier hospitals in London collected between 
29th February and 15th May.  
Legend: The two columns on the right represent the univariate and adjusted effects of the 
corresponding raw variable on the SHR of death vs. discharged alive and the p-values tests the null 
hypothesis that that SHR is 1. A SHR value greater than 1 indicates a harmful effect whilst a value 
less than 1 indicates a protective effect of the corresponding variable on the left. The last column 
represents the most parsimonious model derived from the data. 
Abbreviations:  angiotensin-converting-enzyme inhibitors (ACEi); angiotensin II receptor blockers 
(ARB); arteriovenous graft (AVG); non-invasive ventilation (NIV). Neutrophil/lymphocyte 
(NEUT/LYMP) 
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Table 2 
Variable Summary Hemodialysis population Peritoneal dialysis population 
  St. 
Helier’s 
King’s St. 
George’s 
Pooled SARS-CoV-2 
positive 
P-
value 
St. 
Helier’s 
King’s St. 
George’s 
Pooled SARS-CoV-2 
positive 
P-
value 
Total Number 846 597 294 1737 224  98 90 40 228 10  
Gender Male 61.9% 59% 58.5% 1048(60%) 133(59%) 0.753 55.1% 60% 60% 132(58%) 8 (80%) .198 
Female 28.1% 41% 41.5%  689(40%) 91(41 %)  44.9% 40% 40% 96(42%) 2(20%)  
Ethnicity White 60% 40% 29.9% 834(48%) 85(38%) 0.001 75.5% 37.8% 47.5% 127(56%) 5(50% .754 
Other 35.3% 59.9% 66% 903(52%) 139(62%)  21.4% 62.2% 42.5% 101(44%) 5(50%)  
Missing 4.7% 0.01% 4.1%    3.1% 0% 10%    
Age(years) Median 68.7 63.4 66.6 66.5 65 .384 67.1 56.8 62.5 62.2 69.5 .137 
Q1-Q2 56.4-77.7 53.0-75.1 54.6-75.6  57-77  57.7-76.5 45.5-72.4 50.9-73.8  59-75  
Diabetes No    1360(78%) 103(46%)     185(81%) 4(40%)  
Yes 11.9% 35.5% 21.8% 377(22%) 120 (54%) <0.001 5.1% 28.9% 30% 43(19%) 6(60%) .004 
Table 2 Comparisons between COVID patients characteristics and the whole sample of ICDH/PD 
patients across the 3 hospitals.  
Legend: The pooled proportions and numbers are weighted averages across the three hospitals.  
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Table 3 
  Hemodialysis population Peritoneal dialysis population 
 Total 
RRT  
Total 
ICHD 
SARS-
CoV-2 
Death Case Fatality 
Ratio 
p-
value 
Total 
PD 
SARS-
CoV-2 
Death Case 
Fatality 
Ratio 
p-
value 
All 3 Hospitals  1737 224 51 23%(17%,28%)  - 98 10 6 30% - 
London 14394  1021 219 21%(19%,24%) 0.67   44 12 27% 0.257 
England 56201  2134 502 24%(22%,25%) 0.80  78 25 32% 0.299 
UK 66612  2326 553 24%(22%,26%) 0.74  84 26 31% 0.289 
Table 3 Local and national cumulative numbers as reported until 15th May by the UK Renal Registry.  
Legend: The p-values are consistent with no difference between the case-fatality ratio in our sample 
and those in London, England and UK. Our data suggest some evidence that the case fatality ratio is 
higher in PD than in HD (51/224) and PD (6/10) patients (p=0.015 according to Fisher’s exact test). 
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Table 4 
Variable Category/Summary CEILLING OF CARE ICU admission 
  ALL  
(143) 
WARD 
(73)  
OPTIFLOW/CPAP 
(24) 
INTUBATION 
(46) 
p-value NO (207) YES (11) Miss (6) p-value 
GENDER Male 84(58.7%) 46(63.0%) 9(37.5%) 29(63.0%) 0.068 121(58.5) 8(72.7) 4 (66.7%) 0.348 
 Female 59(41.3 %) 27(37.0%) 15(62.5%) 17(37.0%)  86(41.6) 3(27.3) 2(33.3%)  
ETHNICITY White 58(38%) 28(38.4%) 13(54.2%) 17(36.9%) 0.327 78(37.7) 5(45.6) 2(33.3) 0.605 
(binary) Other 85(62%) 45(61.6%) 11(45.8%) 29(63.1%)  129(62.3) 6(54.6) 4(66.7)  
SMOKING Never 94 (41.9%) 23(31.5%) 11(45.8%) 19(41.3 %) 0.284 86(41.6) 4(36.4) 4(66.7) 0.715 
status Ever 71 (31.7%) 28(38.4%) 10(41.7%) 11(13.9%)  66(31.9) 4(36.4) 1 (16.7)  
 Missing 59 (26.3%) 22(30.1%) 3(12.5%) 16(34.8%)  55(26.6) 3(27.3) 1(16.7)  
AGE Mean (SD) 66.8(14.5) 74.8(8.9) 65.9(12.0) 54.6(14.3) <0.001 66.7(14.0) 49.9(12.5) 4 (66.7%) 0.0004 
at admission Median (Q1-Q3) 70(59-78) 77(70-81) 67(57-72.5) 57(44-62)  68(58-77) 53(40-61) 2(33.3%)  
(5 yrs effect) Range 25-90 37-90 33-87 25-85  26-90 25-63   
BMI Mean (SD) 27.6(7.7) 25.8(4.9) 28.1 (8.9) 30.6(9.8) 0.1263 28.5(7.6) 31.7 (9.9)  0.296 
(kg/m2) Median (Q1-Q3) 25.9(22.3-30.1) 25.8(21.4-29.6) 25.3(22.6-29.0) 27.8(23.2-36.5)  26.2(23.1-30.7) 29.9(24.9-35.4)   
 Range 16.5-57.8 16.7-38.2 16.5-51.7 18.4-52.7  16.5-57.8 21.0-49.2   
 Missing 21(14.5%) 9(12%) 9(12.5%) 9(20%)  21(10%) 545.5%)   
WHO 
Performance 
ststus 
binary 
0-2 76 (53.2 %) 22(30.1 %) 17(70.8%) 37(80.4%) <0.001 120(58%) 8(72.7%) 6(100%) 0.40 
3-4 66 (46.2 %) 51(69.9%) 7(29.2 %) 8(17.4 %)  80(38.7%) 3(27.3%) 0(0%)  
Missing 1(0.7%) 0(0%) 0(0 %) 1(2.2 %)  7(3.4%) 0(0%) 0(0%)  
          
NEUT/LYMP  Mean (SD) 1.74(.78) 1.67(.79) 1.96(.68) 1.75(.81) 0.233 1.54(.76) 2.46(.87)  0.0006 
ratio  Median (Q1-Q3) 1.67(1.25-2.14) 1.63(1.12-2.13) 1.98(1.43-2.44) 1.59(1.25-2.14)  1.53(1.07-1.99) 2.14(1.83-2.90)   
(log scale) Range -.07-4.53 -.07-3.52 .65-2.59 .22-4.53  -.31-3.52 1.47-4.53   
 Missing 2(1.4%) 0(0%) 1(4%) 1(2%)  11(5%) 0(0%)   
Hist of cancer  No 121 (84.62%) 62 (84.93%) 19 (79.17%) 40 (86.96%) 0.688 176(85.02%) 10(90.91%) 3 (50%) 0.999 
 Yes 22(15.38%) 11 (15.07%) 5 (20.83%) 6 (13.04%)  29(14.01%) 1(9.09%) 3(50%)  
 Missing 0(0%) 0(0%) 0(0%) 0(0%)  2(0.97%) 0(0%) 0(0%)  
Hypertension No 27(18.88%) 10 (13.70%) 6 (25%) 11 (23.91%) 0.269 37(17.87%) 3(27.27%) 1(16.67%) 0.430 
 Yes 116(81.12(%) 63 (86.30%) 18 (75%) 35 (76.09%)  169(81.64%) 8(72.73%) 5(83.33%)  
 Missing 0(0%) 0(0%) 0(0%) 0(0%)  1(0.48%) 0(0%) 0(0%)  
DIABETES No 72(50.35%) 32 (43.84%) 13 (54.17%) 27 (58.70%) 0.264 91(43.96%) 10(90.91%) 2(33.33%) 0.003 
 Yes 71 (49.65%) 41 (56.16%) 11 (45.83%) 19 (41.30%)  115(55.56%) 1(9.09%) 4(66.67%)  
 Missing 0(0%) 0(0%) 0(0%) 0(0%)  1(0.48%) 0(0%) 0(0%)  
HFrEF No 118 (83.10%) 54 (73.97%) 22 (91.67%) 42 (93.33%) 0.013 164(79.23%) 11(100%) 6(100%) 0.224 
 Yes 25(16.90%) 20 (26.03%) 2 (8.33%) 3 (6.67%)  40(19.32%) 0(0%) 0(0%)  
 Missing 0(0%) 0(0%) 0(0%) 0(0%)  3(1.45%) 0(0%) 0(0%)  
CHR LUNG No 102 (71.33%) 51 (69.86%) 15 (62.50%) 36 (78.26%) 0.379 154(74.40%) 10(90.91%) 4(66.67%) 0.300 
DISEASE Yes 41 (28.67%) 22 (30.14%) 9 (37.50%) 10 (21.74%)  53(25.60%) 1(9.09%) 2(33.33%)  
Ischaemic 
heart disease 
No 94 (65.73%) 43 (58.90%) 15 (62.50%) 36 (78.26%) 0.083 144(69.57%) 9(81.82%) 4(66.67%) 0.518 
Yes 49 (34.27%) 30 (41.10%) 9 (37.50%) 10 (21.74%)  60(28.99%) 2(18.18%) 2(33.33%)  
Missing 0(0%) 0(0%) 0(0%) 0(0%)  3(1.45%) 0(0%) 0(0%)  
Cerebrovascul
ar disease 
No 106 (74.13%) 46 (63.01%) 18 (75.00%) 42 (91.30%) 0.003 156(75.36%) 11(100%) 6 (100%) 0.073 
Yes 37 (25.87%) 27 (36.99%) 6 (25.00%) 4 (8.70%)  49(23.67%) 0(0%) 0(0%)  
Missing 0 (0%) 0 (0%) 0 (0%) 0 (0%)  0 (0%) 0 (0%) 0 (0%)  
Table 4: Impact of Clinical Variable and comorbidity on Ceiling of care or ICU 
Legend: *Tests are conducted on complete data 
 
 
 
  
28 
 
 
 
 
 
Figure Title and Legends 
Figure 1 The age dependent case fatality ratio and the daily time series of hospital admissions and 
deaths in COVID-19 positive hemodialysis patients. 
Figure 2 The predicted daily cumulative incidence of death and hospital discharge of HD COVID 
positive patients. Legend The curves indicate a short and fast dynamics of death and a long time to 
discharge. 
Figure 3 The dynamics of hospital death and hospital discharge in association with 
neutrophil/lymphocytes ratio. Legend: High levels of this ratio are associated with high risk of in-care 
deaths in COVID-19 positive hemodialysis patients. Low values of this ratio are associated with rapid 
and high probability of hospital discharge. 
Figure 4 Meta-analyses for the pooled case-fatality ratio based on existing research with and without 
current London study 
 
 
Figure 1
Figure 2
Figure 3: Neutrophil/Lymphocyte ratio 
Figure 3
Overall  (I^2 = 58.12%, p = 0.03)
Turkey-Istanbul
US-New York
UK-London
Spain-Madrid
France-Paris
China-Wuhan
Italy-Brescia
Study
0.23 (0.18, 0.29)
0.20 (0.07, 0.41)
0.31 (0.19, 0.44)
0.23 (0.17, 0.29)
0.31 (0.16, 0.48)
0.18 (0.14, 0.24)
0.14 (0.06, 0.27)
0.34 (0.25, 0.45)
ES (95% CI)
  0 .1 .2 .3 .4 .5Proportion
Pooled case-fatality ratio (London included)
Overall  (I^2 = 64.84%, p = 0.01)
US-New York
Study
Spain-Madrid
Turkey-Istanbul
Italy-Brescia
France-Paris
China-Wuhan
0.24 (0.17, 0.31)
0.31 (0.19, 0.44)
ES (95% CI)
0.31 (0.16, 0.48)
0.20 (0.07, 0.41)
0.34 (0.25, 0.45)
0.18 (0.14, 0.24)
0.14 (0.06, 0.27)
  0 .1 .2 .3 .4 .5Proportion
Pooled case-fatality ratio (London excluded)
Figure 4
